Published on in CHOP News
CHOP researchers identified an in vivo role for activated protein C (APC), which could potentially be exploited for future hemophilia A treatments.
Published on in CHOP News
CHOP researchers found the elevated biomarker in all children who tested positive for SARS-CoV-2, whether they were symptomatic for COVID-19 or not.
Published on in CHOP News
Fears of catching Covid-19 in ERs forced many in the throes of pain crises to avoid seeking medical attention. Dr. Kim Smith-Whitley explains the importance of seeking care in a COVID-19 world.
Published on in CHOP News
Millions of Americans carry the sickle cell trait, many without knowing it. Could they be at risk for severe Covid-19? Stat News Reports.
Published on in CHOP News
CHOP researchers show convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19.
Learn how Kim Smith-Whitley, MD, is fighting to improve the lives of her patients in the wake of COVID-19.
Read morePublished on in CHOP News
New treatment developed by CHOP researchers poised to improve sepsis outcomes.
The US Food and Drug Administration has approved two new breakthrough therapies for patients with sickle cell disease (SCD), and we believe both may enhance the treatment of our patients here at CHOP.
Read morePublished on in CHOP in the Media
The US Food and Drug Administration has granted accelerated approval to two novel drugs to treat sickle cell disease.
Published on in CHOP News
Stefano Rivella, PhD, an expert in creating the next-generation lentiviral vectors for the cure of hemoglobinopathies including sickle cell disease (SCD), as well as a leader in the discovery of erythroid and iron disorders including beta-thalassemia, has led three new published studies that make significant contributions to the scientific body of literature regarding red blood cells, and how manipulating the production of red cells can lead to the development of new disease-modifying therapies.